Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
AstraZeneca
Mayo Clinic
Bristol-Myers Squibb
Bayer
Radiopharm Theranostics, Ltd
Tizona Therapeutics, Inc
City of Hope Medical Center
Novartis
Onchilles Pharma Inc
Ocellaris Pharma, Inc.
Fusion Pharmaceuticals Inc.
Innate Pharma
Novartis
OncoNano Medicine, Inc.
Compass Therapeutics
NeoTX Therapeutics Ltd.
Transgene
Bolt Biotherapeutics, Inc.
Strand Therapeutics Inc.
Institut Bergonié
Hadassah Medical Organization
Sichuan Baili Pharmaceutical Co., Ltd.
Institut Curie
Valo Therapeutics Oy
Memgen, Inc.
Incyte Corporation
Cancer Research UK
NuCana plc
Genentech, Inc.
Novartis
UNICANCER
Theratechnologies
University Health Network, Toronto
Seagen Inc.
Stanford University
BioAtla, Inc.
Sotio Biotech Inc.
Simcha IL-18, Inc.
AstraZeneca
Salubris Biotherapeutics Inc
Novartis
Xencor, Inc.
ADC Therapeutics S.A.
Pliant Therapeutics, Inc.
Innolake Biopharm
Eli Lilly and Company
BioEclipse Therapeutics
Hefei TG ImmunoPharma Co., Ltd.